title: Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
abstract: BACKGROUND
  This study was performed to evaluate the tolerability and efficacy of temozolomide and irinotecan as a second-line regimen in recurrent/metastatic non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Patients with recurrent/metastatic NSCLC, including those with treated brain metastases, following one prior platinum-based regimen received temozolomide 75 mg/m daily on days 1 through 15 and irinotecan 100 mg/m on days 8 and 15 every 21 days.
  
  
  RESULTS
  The authors treated 46 patients, of whom more that 90% had a performance status of 0 or 1. Four patients (8.7%) attained partial response and 17 (37.0%) had disease stabilization as their best response. The median time to progression was 1.8 months, median overall survival was 9.8 months, and 1-year overall survival was 34%. Grade 1/2 fatigue (63%), anemia (61%), nausea (52%), and diarrhea (44%) were the most common toxicities. Grade 3/4 leukopenia and diarrhea were each observed in 9% of patients. One unexpected death occurred, possibly related to the regimen.
  
  
  CONCLUSIONS
  Second-line treatment with temozolomide and irinotecan showed tolerable toxicities. The response rates, median survival times, and 1-year survival rates were comparable to other active NSCLC agents.
authors.affiliation: Section of Hematology-Oncology and Phase II Network, University of Chicago Medical Center, Chicago, Illinois 60615, USA.
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Choong
authors.forename: Ann M
authors.initials: AM
authors.lastname: Mauer
authors.forename: Philip C
authors.initials: PC
authors.lastname: Hoffman
authors.forename: Charles M
authors.initials: CM
authors.lastname: Rudin
authors.forename: Jerome D
authors.initials: JD
authors.lastname: Winegarden
authors.forename: J Lee
authors.initials: JL
authors.lastname: Villano
authors.forename: Mark
authors.initials: M
authors.lastname: Kozloff
authors.forename: James L
authors.initials: JL
authors.lastname: Wade
authors.forename: David F
authors.initials: DF
authors.lastname: Sciortino
authors.forename: Livia
authors.initials: L
authors.lastname: Szeto
authors.forename: Everett E
authors.initials: EE
authors.lastname: Vokes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000556:secondary; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016019:Survival Analysis; D000077204:Temozolomide
chemical_list: D000077146:Irinotecan; D003606:Dacarbazine; D002166:Camptothecin; D000077204:Temozolomide